Literature DB >> 3987377

The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction.

D S Postma, G H Koëter, T W vd Mark, R P Reig, H J Sluiter.   

Abstract

The circadian variation of spirometry and blood gases was studied in eight male, normoxemic, patients with chronic air flow obstruction and complaints of early morning dyspnea. The patients were selected for a high amplitude in circadian variation of PEFR. They were treated for eight days with placebo and slow-release terbutaline tablets (5 mg at 8 am and 10 mg at 8 pm). Thereafter, arterial blood gas levels were measured at four-hour intervals over 24 hours. Just after blood sampling, FEV1 measurements were performed. The results on placebo therapy were compared with results in eight healthy volunteers matched for age, sex, and smoking habits. The circadian rhythms of FEV1, PaO2, and SaO2 in these patients showed a higher amplitude than in normal subjects. The decrease of FEV1 in the patient group at 8 am coincided with the decrease in PaO2 and SaO2. In normal subjects no significant nocturnal fall in FEV1, PaO2, or SaO2 occurred. Administration of slow-release terbutaline tablets for eight days, providing comparable diurnal and nocturnal serum levels, prevented the nocturnal decrease of FEV1, PaO2, and SaO2. The increase of the FEV1 at all hours of observation showed a significant correlation with the increase of the PaO2.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987377     DOI: 10.1378/chest.87.5.653

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  [Chronopharmacology--significance for clinical treatment?].

Authors:  B Lemmer
Journal:  Klin Wochenschr       Date:  1989-09-15

Review 2.  Chronopharmacokinetics. Are they clinically relevant?

Authors:  B Lemmer; B Bruguerolle
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

3.  Circadian change in bronchial responsiveness and airflow obstruction in asthmatic children.

Authors:  W M van Aalderen; D S Postma; G H Koëter; K Knol
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

4.  The Utility of the Swine Model to Assess Biological Rhythms and Their Characteristics during Different Stages of Residence in a Simulated Intensive Care Unit: A Pilot Study.

Authors:  Katrina N Leyden; Sandra K Hanneman; Nikhil S Padhye; Michael H Smolensky; Duck-Hee Kang; Diana Shu-Lian Chow
Journal:  Chronobiol Int       Date:  2015       Impact factor: 2.877

5.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Authors:  P M A Calverley; A Lee; L Towse; J van Noord; T J Witek; S Kelsen
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

6.  Underdiagnosed asthma in South Australia.

Authors:  R J Adams; D H Wilson; S Appleton; A Taylor; E Dal Grande; C R Chittleborough; R E Ruffin
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

7.  Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma.

Authors:  A Wallin; B Melander; L Rosenhall; T Sandström; L Wåhlander
Journal:  Thorax       Date:  1990-04       Impact factor: 9.139

8.  Comparison of the variability of the annual rates of change in FEV₁ determined from serial measurements of the pre- versus post-bronchodilator FEV₁ over 5 years in mild to moderate COPD: results of the lung health study.

Authors:  Donald P Tashkin; He-Jing Wang; David Halpin; Eric C Kleerup; John Connett; Ning Li; Robert Elashoff
Journal:  Respir Res       Date:  2012-08-15

9.  Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study.

Authors:  Yeon Jae Kim; Byung Ki Lee; Chi Young Jung; Young June Jeon; Dae Sung Hyun; Kyung Chan Kim; Sung Ken Yu; Hye Sook Choi; Won Hyuk Shin; Kwan Ho Lee
Journal:  Korean J Intern Med       Date:  2012-11-27       Impact factor: 2.884

10.  Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.

Authors:  Jutta Beier; Anne-Marie Kirsten; Robert Mróz; Rosa Segarra; Ferran Chuecos; Cynthia Caracta; Esther Garcia Gil
Journal:  COPD       Date:  2013-07-02       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.